581 related articles for article (PubMed ID: 19068246)
21. Role of ryanodine receptor mutations in cardiac pathology: more questions than answers?
Thomas NL; George CH; Lai FA
Biochem Soc Trans; 2006 Nov; 34(Pt 5):913-8. PubMed ID: 17052226
[TBL] [Abstract][Full Text] [Related]
22. Genotypic heterogeneity and phenotypic mimicry among unrelated patients referred for catecholaminergic polymorphic ventricular tachycardia genetic testing.
Tester DJ; Arya P; Will M; Haglund CM; Farley AL; Makielski JC; Ackerman MJ
Heart Rhythm; 2006 Jul; 3(7):800-5. PubMed ID: 16818210
[TBL] [Abstract][Full Text] [Related]
23. A novel mutation in FKBP12.6 binding region of the human cardiac ryanodine receptor gene (R2401H) in a Japanese patient with catecholaminergic polymorphic ventricular tachycardia.
Aizawa Y; Ueda K; Komura S; Washizuka T; Chinushi M; Inagaki N; Matsumoto Y; Hayashi T; Takahashi M; Nakano N; Yasunami M; Kimura A; Hiraoka M; Aizawa Y
Int J Cardiol; 2005 Mar; 99(2):343-5. PubMed ID: 15749201
[TBL] [Abstract][Full Text] [Related]
24. Unraveling the mechanisms of catecholaminergic polymorphic ventricular tachycardia.
Iyer V; Armoundas AA
Conf Proc IEEE Eng Med Biol Soc; 2006; Suppl():6761-4. PubMed ID: 17959506
[TBL] [Abstract][Full Text] [Related]
25. Enhanced store overload-induced Ca2+ release and channel sensitivity to luminal Ca2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death.
Jiang D; Wang R; Xiao B; Kong H; Hunt DJ; Choi P; Zhang L; Chen SR
Circ Res; 2005 Nov; 97(11):1173-81. PubMed ID: 16239587
[TBL] [Abstract][Full Text] [Related]
26. RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT.
Kryshtal DO; Blackwell DJ; Egly CL; Smith AN; Batiste SM; Johnston JN; Laver DR; Knollmann BC
Circ Res; 2021 Feb; 128(3):321-331. PubMed ID: 33297863
[TBL] [Abstract][Full Text] [Related]
27. Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations.
Swan H; Laitinen P; Kontula K; Toivonen L
J Cardiovasc Electrophysiol; 2005 Feb; 16(2):162-6. PubMed ID: 15720454
[TBL] [Abstract][Full Text] [Related]
28. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia.
Hayashi M; Denjoy I; Extramiana F; Maltret A; Buisson NR; Lupoglazoff JM; Klug D; Hayashi M; Takatsuki S; Villain E; Kamblock J; Messali A; Guicheney P; Lunardi J; Leenhardt A
Circulation; 2009 May; 119(18):2426-34. PubMed ID: 19398665
[TBL] [Abstract][Full Text] [Related]
29. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
[TBL] [Abstract][Full Text] [Related]
30. Ryanodine receptor and calsequestrin in arrhythmogenesis: what we have learnt from genetic diseases and transgenic mice.
Liu N; Rizzi N; Boveri L; Priori SG
J Mol Cell Cardiol; 2009 Feb; 46(2):149-59. PubMed ID: 19027025
[TBL] [Abstract][Full Text] [Related]
31. Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes.
George CH; Higgs GV; Lai FA
Circ Res; 2003 Sep; 93(6):531-40. PubMed ID: 12919952
[TBL] [Abstract][Full Text] [Related]
32. Impaired Dynamic Sarcoplasmic Reticulum Ca Buffering in Autosomal Dominant CPVT2.
Wleklinski MJ; Kryshtal DO; Kim K; Parikh SS; Blackwell DJ; Marty I; Iyer VR; Knollmann BC
Circ Res; 2022 Sep; 131(8):673-686. PubMed ID: 36102198
[TBL] [Abstract][Full Text] [Related]
33. Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.
Alcalai R; Wakimoto H; Arad M; Planer D; Konno T; Wang L; Seidman JG; Seidman CE; Berul CI
J Cardiovasc Electrophysiol; 2011 Mar; 22(3):316-24. PubMed ID: 20807279
[TBL] [Abstract][Full Text] [Related]
34. The clinical and genetic spectrum of catecholaminergic polymorphic ventricular tachycardia: findings from an international multicentre registry.
Roston TM; Yuchi Z; Kannankeril PJ; Hathaway J; Vinocur JM; Etheridge SP; Potts JE; Maginot KR; Salerno JC; Cohen MI; Hamilton RM; Pflaumer A; Mohammed S; Kimlicka L; Kanter RJ; LaPage MJ; Collins KK; Gebauer RA; Temple JD; Batra AS; Erickson C; Miszczak-Knecht M; Kubuš P; Bar-Cohen Y; Kantoch M; Thomas VC; Hessling G; Anderson C; Young ML; Choi SHJ; Cabrera Ortega M; Lau YR; Johnsrude CL; Fournier A; Van Petegem F; Sanatani S
Europace; 2018 Mar; 20(3):541-547. PubMed ID: 28158428
[TBL] [Abstract][Full Text] [Related]
35. Ablation of HRC alleviates cardiac arrhythmia and improves abnormal Ca handling in CASQ2 knockout mice prone to CPVT.
Liu B; Ho HT; Brunello L; Unudurthi SD; Lou Q; Belevych AE; Qian L; Kim DH; Cho C; Janssen PM; Hund TJ; Knollmann BC; Kranias EG; Györke S
Cardiovasc Res; 2015 Nov; 108(2):299-311. PubMed ID: 26410369
[TBL] [Abstract][Full Text] [Related]
36. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells.
Itzhaki I; Maizels L; Huber I; Gepstein A; Arbel G; Caspi O; Miller L; Belhassen B; Nof E; Glikson M; Gepstein L
J Am Coll Cardiol; 2012 Sep; 60(11):990-1000. PubMed ID: 22749309
[TBL] [Abstract][Full Text] [Related]
37. Description of a novel RyR2 mutation in a juvenile patient with symptomatic catecholaminergic polymorphic ventricular tachycardia in sleep and during exercise: a case report.
Seidlmayer LK; Riediger F; Pagonas N; Nordbeck P; Ritter O; Sasko B
J Med Case Rep; 2018 Oct; 12(1):298. PubMed ID: 30296944
[TBL] [Abstract][Full Text] [Related]
38. The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading frame mutational analysis.
Medeiros-Domingo A; Bhuiyan ZA; Tester DJ; Hofman N; Bikker H; van Tintelen JP; Mannens MM; Wilde AA; Ackerman MJ
J Am Coll Cardiol; 2009 Nov; 54(22):2065-74. PubMed ID: 19926015
[TBL] [Abstract][Full Text] [Related]
39. Unusual clinical presentation in a family with catecholaminergic polymorphic ventricular tachycardia due to a G14876A ryanodine receptor gene mutation.
Allouis M; Probst V; Jaafar P; Schott JJ; Le Marec H
Am J Cardiol; 2005 Mar; 95(5):700-2. PubMed ID: 15721128
[TBL] [Abstract][Full Text] [Related]
40. Spectrum and prevalence of cardiac ryanodine receptor (RyR2) mutations in a cohort of unrelated patients referred explicitly for long QT syndrome genetic testing.
Tester DJ; Kopplin LJ; Will ML; Ackerman MJ
Heart Rhythm; 2005 Oct; 2(10):1099-105. PubMed ID: 16188589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
